KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Other Working Capital Changes (2016 - 2025)

Nektar Therapeutics (NKTR) has 16 years of Other Working Capital Changes data on record, last reported at $618000.0 in Q3 2025.

  • For Q3 2025, Other Working Capital Changes fell 82.73% year-over-year to $618000.0; the TTM value through Sep 2025 reached $8.0 million, up 205.06%, while the annual FY2024 figure was $4.2 million, 216.86% up from the prior year.
  • Other Working Capital Changes reached $618000.0 in Q3 2025 per NKTR's latest filing, up from -$985000.0 in the prior quarter.
  • Across five years, Other Working Capital Changes topped out at $10.8 million in Q3 2021 and bottomed at -$6.2 million in Q1 2021.
  • Average Other Working Capital Changes over 5 years is $98684.2, with a median of $618000.0 recorded in 2025.
  • Peak YoY movement for Other Working Capital Changes: plummeted 322.03% in 2021, then soared 510.45% in 2025.
  • A 5-year view of Other Working Capital Changes shows it stood at $3.4 million in 2021, then tumbled by 160.15% to -$2.0 million in 2022, then surged by 142.4% to $867000.0 in 2023, then surged by 179.82% to $2.4 million in 2024, then plummeted by 74.53% to $618000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Other Working Capital Changes were $618000.0 in Q3 2025, -$985000.0 in Q2 2025, and $6.0 million in Q1 2025.